Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409795 · ClinicalTrials.gov registry record · Phase 2
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
A Phase 2 study, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04409795 is a Phase 2 study that has completed, run by Joslin Diabetes Center. The registered enrollment target is 3 participants.
The verdict
NCT04409795, a Phase 2 study, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of adding oral hypoglycemic agents (OHA) to existing insulin treatment in monogenic variant carriers of the Joslin 50-Year Medalist Study ("Medalists"), who are characterized by ≥50 years of insulin-dependent diabetes. Our primary objective is to evaluate whether the presence of human leukocyte antigen (HLA) high-risk alleles for diabetes (DR3 and/or DR4) can affect the effectiveness of OHA in these subjects.
Interventions
- DRUG Sitagliptin
- DRUG Metformin Extended Release Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04409795
The ClinicalTrials.gov registry entry for NCT04409795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT04409795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04409795 about?
NCT04409795 is a clinical study titled "Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study". The purpose of this study is to evaluate the efficacy of adding oral hypoglycemic agents (OHA) to existing insulin treatment in monogenic variant carriers of the Joslin 50-Year Medalist Study ("Medalists"), who are characterized by ≥50 years of insulin-dependent diabetes. Our primary objective is to...
What is the current status of trial NCT04409795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-08-26. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04409795?
The interventions under investigation include: Sitagliptin (DRUG), Metformin Extended Release Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04409795?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.